Global Expertise and AI Precision: Transforming Diagnostics Worldwide
Pathology is fundamental to global health, with 90% of diagnoses relying on it. However, the current number of pathologists is insufficient to meet the escalating demand.
Timely diagnoses, optimal treatment plans, and breakthrough cures are critical. Delays in diagnosis and decision-making not only cause distress during emotionally charged times but also adversely impact health outcomes.
It is imperative to advance the pathology industry into the information age.
Transitioning from traditional methods to artificial intelligence
Our mission is to enhance the efficiency of pathologists by optimizing every aspect of the pathology process—from capturing high quality digital images, to building global pathology networks, to AI-driven image analysis and comprehensive pathology-led clinical trial support.
Through our advanced AI systems, esteemed pathologists are equipped with a sophisticated platform of images and information, enabling precise identification and allowing them to focus on critical aspects of their work.
Deciphex’s three brands each play a vital role in this transformative future:
An AI-powered digital platform that streamlines regulated research workflows, thereby enhancing drug safety for all stakeholders.
A global network of expert subspecialty pathologists, connected through a state-of-the-art digital platform, ensures timely, accurate, and high-quality diagnostic services accessible around the clock.
These initiatives represent the initial steps in our efforts to revolutionize the field of pathology.
We are committed to continuously retraining our AI models to deliver deeper insights, invigorating the industry by showcasing the potential and innovative future of pathology, and empowering our distinguished pathologists to offer second opinions pro bono in underserved regions.
Ultimately, our dedication is to ensure that every patient worldwide receives accurate diagnoses and effective treatments promptly.
The Team
Advisors
Dr. Gareth Bryson is the first Head of Clinical Services at the newly integrated Queen Elizabeth University Hospital, Glasgow, and serves as the Digital Pathology Lead for Scotland. A specialist in gynaecological pathology, he has spearheaded the iCAIRD project to create the largest digital pathology service in Europe. With honorary academic roles at the University of Glasgow and the University of St Andrews, Dr. Bryson's leadership in laboratory modernisation and digital pathology makes him a key contributor to Deciphex's mission of advancing diagnostic pathology.
Dr. Steven R. Tahan is a renowned U.S.-based pathologist and Associate Professor of Pathology at Harvard Medical School, where he also serves as Program Director for the BIDMC-Harvard Dermatopathology Fellowship. As Director of Dermatopathology at Beth Israel Deaconess Medical Center, Dr. Tahan is an expert in skin-related pathologies, with a focus on cutaneous oncology and the diagnostic differentiation between benign and malignant skin conditions. Widely published and actively engaged in research, his extensive experience makes him a valuable advisor in advancing Deciphex’s mission in diagnostic pathology.
Dr. Andrew Gallimore is a Consultant Pathologist with a special interest in Head & Neck pathology. After training at Hammersmith Hospital and in Australia, he served as Senior Lecturer and Honorary Consultant at UCL, overseeing The Royal Nose, Throat, and Ear Hospital, London. Dr. Gallimore co-founded what is now the largest independent provider of diagnostic cellular pathology services in the UK and has been an early advocate for digital pathology. As a member of Diagnexia's Scientific Advisory Board, his extensive experience in both the NHS and private sector will contribute to Deciphex’s growth and innovation in the UK and beyond.
Dr. Kenneth Fleming is a distinguished pathologist with a career spanning over four decades, including leadership roles such as Dean of Clinical Medicine and Head of the Medical Sciences Division at the University of Oxford. His groundbreaking research in liver disease, molecular pathology, and evidence-based pathology has earned him over 200 peer-reviewed publications and international recognition. A pioneer in global health initiatives, Dr. Fleming notably set up a pathology teaching program in Zambia to raise standards in developing countries. He also led the drive to have a World Health Assembly adoption of a resolution on the fundamental importance of diagnostics in healthcare in May 2023. His expertise is invaluable to Deciphex's mission of advancing diagnostic pathology globally.
Dr. Paul Waring is a renowned anatomical and molecular pathologist, recognized for pioneering the application of genomic technologies in cancer diagnostics and drug development. He established one of the world’s first molecular diagnostics labs in both the public sector at Peter MacCallum Cancer Centre and the private sector at Genentech, significantly advancing personalized medicine. With leadership roles at institutions like Genentech and Roche Diagnostics, and over 140 publications, Dr. Waring's decades of expertise make him a key advisor in shaping Deciphex's future.
Dr. Ortiz-Villalon is an internationally recognized expert in cancer care and interstitial lung diseases, with a strong focus on immune-oncology, artificial intelligence, and antibody drug conjugates in lung and gastrointestinal cancers. He has held leadership roles, including Senior Leader in Medical Affairs Diagnostics at AstraZeneca and Head of Clinical Pathology and Cancer Diagnostics at Karolinska University Hospital, one of the world’s top hospitals. As the co-founder and Chief Medical Officer of Pathology Science, Dr. Cris is dedicated to advancing digital pathology globally, making him a vital contributor to Deciphex’s mission and vision.
Dr. Page Bouchard is a veterinary toxicologic pathologist and consultant with over 30 years of experience in the pharmaceutical and biotechnology industries. Formerly the Chief Scientific Officer and Head of Research and Early Development for Novartis Gene Therapies, he led the AAV gene therapy research platform and pipeline. Dr. Bouchard also served as Global Head of Preclinical Safety at Novartis Institutes for BioMedical Research, overseeing a team of 250 associates responsible for nonclinical safety assessment globally. His extensive experience across gene therapies, biologics, and novel therapeutic platforms, along with his intimate knowledge of AI’s potential in pathology, makes him an invaluable advisor in helping Deciphex meet the evolving needs of the pharma industry.
Investors
.png)
Partners
Awards
/
6
Recognising Innovation and Excellence
Deciphex is proud to be recognized for our innovative impact in AI-driven pathology. These awards highlight our commitment to transforming healthcare, improving patient outcomes, and advancing digital pathology on a global scale.